Featured Videos

The SynBioBeta conference was held last week in Oakland, CA. Julianna LeMieux, PhD, Deputy Editor in Chief at GEN was on the ground. Here, she takes a moment to fill in Kevin Davies, PhD, GEN’s Editor at Large, on the latest news from the meeting. The bottom line is, SynBioBeta is bigger than ever and shows no signs of slowing down.

Excitement in Oakland: A Report from SynBioBeta

Rachel King is a trailblazer in biotech, a venture capitalist turned co-founder and CEO, now turned industry leader. As CEO of the Biotechnology Innovation Organization (BIO), King has focused in recent months on stabilizing the leadership and direction of the 1,000-plus member industry group, where the long tenure of Jim Greenwood was followed by the relatively short tenure of Michelle McMurry Heath, MD—about two years, ending last October.
  King is also leading BIO’s ramp-up toward its 2023 BIO International Convention, to be held June 5-8 at the Boston Convention & Exhibition Center, and overseeing the organization’s response to a series of challenges to the industry. These challenges range from articulating industry’s perspective on pricing prescription drugs following enactment of the “Inflation Reduction Act” last year, to preserving access to the most widely used abortion pill, mifepristone in the face of a court challenge by opponents of abortion rights. King is a former chair of BIO, and previously served as CEO of GlycoMimetics, a late clinical-stage biotechnology company she co-founded. GlycoMimetics focuses on discovering and developing glycobiology-based therapies for cancers and inflammatory diseases. Before GlycoMimetics, King was a one-time Entrepreneur in Residence at venture capital firm New Enterprise Associates (NEA). Speaking with GEN senior business editor Alex Philippidis, Rachel recounts her multi-faceted career in biotech, and assesses the industry’s progress and continuing challenges in ensuring federal funding for basic research, advancing newer technologies such as synthetic biology and cell and gene therapy; and diversifying the industry’s workforce.

BIO CEO Rachel King Outlines Industry’s Challenges on “Close to the Edge”

Load More

Latest from GEN Edge

Latest Webinars, GEN Live, Virtual Events, eBooks, & Podcasts

May 2023 issue cover

It’s time to grease the wheels of industry—so declares anyone who wants cell and gene therapies produced in greater volume. To date, these therapies have been artisanal products, much to the frustration of developers, manufacturers, clinicians, and (most of all) patients. Fortunately, cell and gene therapy assembly lines are being assembled thanks to innovations in low-volume analytics, vector optimization, bioreactor control, and workflow automation. All of these developments are discussed in the May issue of GEN, which also considers how the image of fast-turning wheels is especially apt for synbio-powered biomanufacturing. There, the whole idea is to set up iterative design–build–test–learn cycles. To keep these wheels spinning, synbio startups are using AI-powered software to drive automated laboratory evolution. Finally, the May issue of GEN reports on the pharma industry’s RSV vaccines, the antibody industry’s bispecific constructs, gene editing’s clinical progress, and mass spec’s proteomics-friendly turn.